Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health
Renalyx will continue operating as an independent unit within the group
Renalyx will continue operating as an independent unit within the group
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
Subscribe To Our Newsletter & Stay Updated